Importantly, we demonstrated synergistic enhancement of apoptosis and ferroptosis in BL cells upon co-treatment with DhL and an SLC7A11 inhibitor (HG106), suggesting a potential therapeutic strategy for BL. This evidence concerns the gene SLC7A11 and Burkitt lymphoma.